{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T23:38:22Z","timestamp":1722123502597},"reference-count":34,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0374","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T08:21:20Z","timestamp":1637742080000},"source":"Crossref","is-referenced-by-count":10,"title":["Recommendations on the in-hospital treatment of patients with COVID-19"],"prefix":"10.3238","author":[{"given":"Stefan","family":"Kluge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob J.","family":"Malin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver J.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Karagiannidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"10.3238\/arztebl.m2021.0374_ref1","doi-asserted-by":"crossref","unstructured":"Kluge S, Janssens U, Welte T, Weber-Carstens S, Marx G, Karagiannidis C: [Recommendations for critically ill patients with COVID-19]. Med Klin Intensivmed Notfmed 2020; 115: 175\u20137","DOI":"10.1007\/s00063-020-00674-3"},{"key":"10.3238\/arztebl.m2021.0374_ref2","doi-asserted-by":"crossref","unstructured":"Malin JJ, Spinner CD, Janssens U, et al.: Key summary of German national treatment guidance for hospitalized COVID-19 patients: Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021). Infection 2021: 1\u201314","DOI":"10.1007\/s15010-021-01665-y"},{"key":"10.3238\/arztebl.m2021.0374_ref3","doi-asserted-by":"crossref","unstructured":"Kluge S, Janssens U, Spinner CD, Pfeifer M, Marx G, Karagiannidis C: Clinical practice guideline: Recommendations on in-hospital treatment of patients with COVID-19. Dtsch Arztebl Int 2021; 118: 1\u20137","DOI":"10.3238\/arztebl.m2021.0110"},{"key":"10.3238\/arztebl.m2021.0374_ref4","unstructured":"AWMF: S3-Leitlinie: Empfehlungen zur station\u00e4ren Therapie von Patienten mit COVID-19 \u2013 Living Guideline (Stand 10\/2021). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF); 2021. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/113-001LG.html (last accessed on 2 November 2021)."},{"key":"10.3238\/arztebl.m2021.0374_ref5","doi-asserted-by":"crossref","unstructured":"Grieco DL, Menga LS, Cesarano M, et al.: Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: The HENIVOT randomized clinical trial. JAMA 2021; 325: 1731\u201343","DOI":"10.1001\/jama.2021.4682"},{"key":"10.3238\/arztebl.m2021.0374_ref6","unstructured":"Ehrmann S, Li J, Ibarra-Estrada M, et al.: Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med 2021; S2213\u20132600(21)00356\u20138.Epub ahead of print."},{"key":"10.3238\/arztebl.m2021.0374_ref7","doi-asserted-by":"crossref","unstructured":"Alhazzani W, Evans L, Alshamsi F, et al.: Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med 2021; 49: e219\u2013e34","DOI":"10.1097\/CCM.0000000000004899"},{"key":"10.3238\/arztebl.m2021.0374_ref8","unstructured":"Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie & Intensivmedizin: S3-Leitlinie: Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. www.awmf.org. 2017 (last accessed on 2 November 2021)"},{"key":"10.3238\/arztebl.m2021.0374_ref9","doi-asserted-by":"crossref","unstructured":"Patell R, Chiasakul T, Bauer E, Zwicker JI: Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost 2021; 121: 76\u201385","DOI":"10.1055\/s-0040-1721664"},{"key":"10.3238\/arztebl.m2021.0374_ref10","doi-asserted-by":"crossref","unstructured":"Sadeghipour P, Talasaz AH, Rashidi F, et al.: Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. Jama 2021; 325: 1620\u201330","DOI":"10.1001\/jama.2021.4152"},{"key":"10.3238\/arztebl.m2021.0374_ref11","doi-asserted-by":"crossref","unstructured":"Perepu US, Chambers I, Wahab A, et al.: Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19: 2225\u201334","DOI":"10.1111\/jth.15450"},{"key":"10.3238\/arztebl.m2021.0374_ref12","doi-asserted-by":"crossref","unstructured":"Lawler PR, Goligher EC, Berger JS, et al.: Therapeutic anticoagulation with heparin in noncritically Ill patients with Covid-19. N Engl J Med 2021; 385: 790\u2013802","DOI":"10.1056\/NEJMoa2105911"},{"key":"10.3238\/arztebl.m2021.0374_ref13","doi-asserted-by":"crossref","unstructured":"Lemos ACB, do Esp\u00edrito Santo DA, Salvetti MC, et al.: Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res 2020; 196: 359\u201366","DOI":"10.1016\/j.thromres.2020.09.026"},{"key":"10.3238\/arztebl.m2021.0374_ref14","doi-asserted-by":"crossref","unstructured":"Goligher EC, Bradbury CA, McVerry BJ, et al.: Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med 2021; 385: 777\u201389","DOI":"10.1056\/NEJMoa2103417"},{"key":"10.3238\/arztebl.m2021.0374_ref15","doi-asserted-by":"crossref","unstructured":"Evans L, Rhodes A, Alhazzani W, et al.: Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med 2021; 47: 1181\u20131247","DOI":"10.1007\/s00134-021-06506-y"},{"key":"10.3238\/arztebl.m2021.0374_ref16","doi-asserted-by":"crossref","unstructured":"Kreuzberger N, Hirsch C, Chai KL, et al.: SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev 2021; 9: CD013825","DOI":"10.1002\/14651858.CD013825.pub2"},{"key":"10.3238\/arztebl.m2021.0374_ref17","doi-asserted-by":"crossref","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, et al.: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384: 238\u201351","DOI":"10.1056\/NEJMoa2035002"},{"key":"10.3238\/arztebl.m2021.0374_ref18","doi-asserted-by":"crossref","unstructured":"O\u2018Brien MP, Forleo-Neto E, Musser BJ, et al.: Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med 2021; 385: 1184\u201395","DOI":"10.1056\/NEJMc2113862"},{"key":"10.3238\/arztebl.m2021.0374_ref19","doi-asserted-by":"crossref","unstructured":"Lundgren JD, Grund B, Barkauskas CE, et al.: A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med 2021; 384: 905\u201314","DOI":"10.1056\/NEJMoa2033130"},{"key":"10.3238\/arztebl.m2021.0374_ref20","doi-asserted-by":"crossref","unstructured":"Ansems K, Grundeis F, Dahms K, et al.: Remdesivir for the treatment of COVID‐-19. Cochrane Database Syst Rev 2021; 8: CD014962","DOI":"10.1002\/14651858.CD014962"},{"key":"10.3238\/arztebl.m2021.0374_ref21","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.: Remdesivir for the Treatment of Covid-19\u2014final report. N Engl J Med 2020; 383: 1813\u201326","DOI":"10.1056\/NEJMc2022236"},{"key":"10.3238\/arztebl.m2021.0374_ref22","doi-asserted-by":"crossref","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.: Repurposed antiviral drugs for Covid-19\u2014Interim WHO solidarity trial results. N Engl J Med 2021; 384: 497\u2013511","DOI":"10.1056\/NEJMoa2023184"},{"key":"10.3238\/arztebl.m2021.0374_ref23","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M, et al.: Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021; S1473\u20133099(21)00485\u20130. Epub ahead of print."},{"key":"10.3238\/arztebl.m2021.0374_ref24","doi-asserted-by":"crossref","unstructured":"Piechotta V, Chai KL, Valk SJ, et al.: Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020; 7: CD013600","DOI":"10.1002\/14651858.CD013600.pub2"},{"key":"10.3238\/arztebl.m2021.0374_ref25","doi-asserted-by":"crossref","unstructured":"Popp M, Stegemann M, Riemer M, et al.: Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 10: CD015025","DOI":"10.1002\/14651858.CD015025"},{"key":"10.3238\/arztebl.m2021.0374_ref26","doi-asserted-by":"crossref","unstructured":"Popp M, Stegemann M, Metzendorf MI, et al.: Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021; 7: CD015017","DOI":"10.1002\/14651858.CD015017"},{"key":"10.3238\/arztebl.m2021.0374_ref27","doi-asserted-by":"crossref","unstructured":"Wagner C, Griesel M, Mikolajewska A, et al.: Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8: CD014963","DOI":"10.1002\/14651858.CD014963"},{"key":"10.3238\/arztebl.m2021.0374_ref28","doi-asserted-by":"crossref","unstructured":"Ghosn L, Chaimani A, Evrenoglou T, et al.: Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev 2021; 3: CD013881","DOI":"10.1002\/14651858.CD013881"},{"key":"10.3238\/arztebl.m2021.0374_ref29","unstructured":"RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637\u201345"},{"key":"10.3238\/arztebl.m2021.0374_ref30","unstructured":"Tharaux P, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M: Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med 2021; 9: 295\u2013304"},{"key":"10.3238\/arztebl.m2021.0374_ref31","doi-asserted-by":"crossref","unstructured":"Kyriazopoulou E, Poulakou G, Milionis H, et al.: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 2021; 27: 1752\u201360","DOI":"10.1038\/s41591-021-01499-z"},{"key":"10.3238\/arztebl.m2021.0374_ref32","doi-asserted-by":"crossref","unstructured":"Murai IH, Fernandes AL, Sales LP, et al.: Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA 2021; 325: 1053\u201360","DOI":"10.1001\/jama.2020.26848"},{"key":"10.3238\/arztebl.m2021.0374_ref33","doi-asserted-by":"crossref","unstructured":"Mikolajewska A, Fischer AL, Piechotta V, et al.: Colchicine for the treatment of COVID‐-19. Cochrane Database Syst Rev 2021; 10: CD01504","DOI":"10.1002\/14651858.CD015045"},{"key":"10.3238\/arztebl.m2021.0374_ref34","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection: A minimal common outcome measure set for COVID-19 clinical researchLancet Infect Dis 2020; Lancet Infect Dis. 2020; 20: e192\u2013e197"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T09:40:34Z","timestamp":1638956434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":34,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0374","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,17]]}}}